Indoco Remedies Ltd
Indoco Remedies Ltd is a pharmaceutical company that develops, manufactures, and markets generic and branded formulations of prescription drugs, primarily in India and international markets.
Business. Indoco Remedies Ltd (INRM.NS) is a pharmaceutical company headquartered in India that operates within the healthcare sector. The firm is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Indoco Remedies Ltd (INRM.NS) is a pharmaceutical company headquartered in India that operates within the healthcare sector. The firm is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.
Indoco Remedies Ltd has a debt-to-equity ratio of 0.97, indicating a moderate level of leverage, and a current ratio of 1.24, suggesting limited short-term liquidity cushion. The company reported negative free cash flow of -3341675000 INR and capital expenditure of -3561538000 INR, reflecting significant reinvestment in operations. The negative net cash position after subtracting total debt raises concerns about liquidity risk.
The company's profitability metrics are weak, with a return on equity of -7.21% and a return on assets of -3.03%, both significantly below the industry median for pharmaceutical firms. Operating income was -128564000 INR, and net income was -737369000 INR, indicating a challenging operating environment. Gross profit of 11010366000 INR suggests some pricing power, but this is insufficient to offset operational costs and debt servicing.
Indoco Remedies Ltd's revenue of 16649194000 INR is derived from a mix of domestic and international markets, though the exact geographic breakdown is not disclosed. The company's exposure to international markets may introduce currency and regulatory risks, particularly in emerging markets. The lack of segment-specific revenue data limits the ability to assess concentration risk in detail.
The company's growth trajectory is uncertain, with no clear revenue growth or margin expansion in the most recent period. Analysts have assigned a mean price target of 246.50 INR and a median price target of 244.50 INR, with all three recommendations being "hold". This suggests limited upside potential in the near term, with no strong buy or buy ratings from analysts.
Risk factors include liquidity constraints, negative free cash flow, and weak profitability. The company's dilution risk is currently assessed as low, but the negative net cash position and high leverage could increase the likelihood of equity issuance in the future. No recent filings or transcripts indicate material changes in the company's strategic direction or operational performance.
Recent events, including analyst estimates and price targets, suggest a cautious outlook. The absence of strong buy ratings and the concentration of "hold" recommendations indicate that the market is not currently pricing in significant growth or transformation.
- Indoco Remedies Ltd is a pharmaceutical company with a moderate debt load and weak profitability metrics.
- The company's return on equity and return on assets are significantly below industry medians, indicating poor capital efficiency.
- Liquidity is constrained, with negative free cash flow and a current ratio of 1.24.
- Analysts have assigned a neutral outlook, with all three recommendations being "hold."
- The company's geographic and segment exposure is not fully disclosed, limiting visibility into concentration risk.
- The risk of dilution is currently low, but liquidity pressures could change this in the future.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -9,20 |
| Revenue | —no estimate | —no estimate | 17,6B INR |
| Operating income | —no estimate | —no estimate | -124,5M INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Indoco Remedies Ltd Market data — financials · 2026-05-28
- Indoco Remedies Ltd Market data — analyst estimates · 2026-05-28